- Thermo Fisher Scientific
- BioLife Solutions
- Merck KGaA/MilliporeSigma
- STEMCELL Technologies
- Corning Life Sciences (including Axygen, Falcon consumables)
- Bio-Rad Laboratories
- CTS Bio
- HiMedia Laboratories
- AMSBIO
- BioGenuix MedSystems
- Cryo-BioSystems
- Lonza
- VWR/Avantor
- Sakura Finetek
- StemCyte
- BioLife
- Fujifilm Wako/Toyo
- Thermogenesis
- CryoSafe
1. BioLife Solutions
-
Offerings: Cryopreservation media and storage systems
-
Contributions: Standardizing protocols and enabling cell viability
-
Key Products: Cryo-bags and controlled-rate freezers for clinical workflows
2. STEMCELL Technologies
-
Offerings: Research media and cryopreservation reagents
-
Contributions: Advancing reproducibility and protocol guidance globally
-
Key Products: Freezing media kits, cryo-solutions, validated protocols
3. Corning Life Sciences
-
Offerings: Labware, cryovials, plates, and consumables
-
Contributions: Improving sample handling standards
-
Key Products: Falcon tubes, Axygen vials, and specialized plastics globally
4. Bio-Rad Laboratories
-
Offerings: Quality control assays and cryo reagents
-
Contributions: Ensuring assay reliability and storage confidence
-
Key Products: Validation kits and cold-chain monitoring tools
5. CTS Bio
-
Offerings: Custom cryopreservation solutions and services
-
Contributions: Supporting bespoke workflows for clinical research
-
Key Products: Tailored media, consultancy, and on-demand support
Company Landscape
Top Company 1: Thermo Fisher Scientific Inc.
Company Overview
- Corporate Information:
- Headquarters: Waltham, Massachusetts, U.S.
- Year Founded: 2006 (through the merger of Thermo Electron and Fisher Scientific)
- Ownership Type: Public (NYSE: TMO)
- History and Background:
- Formed from the merger of Thermo Electron Corporation (founded 1956) and Fisher Scientific International Inc. (founded 1902).
- Has grown through significant strategic acquisitions to become a world leader in serving science.
- Key Milestones/Timeline:
- 2006: Merger of Thermo Electron and Fisher Scientific to form Thermo Fisher Scientific.
- 2014: Acquired Life Technologies, significantly expanding its presence in life sciences, including cell culture and cryopreservation.
- Ongoing: Continuous expansion of the Gibco brand, a key provider of cell freezing media.
- Business Overview:
- A global provider of scientific instrumentation, reagents and consumables, and software services. A key focus is on enabling customers in life sciences research, clinical diagnostics, and pharmaceutical production.
- Business Segments/Divisions:
- Life Sciences Solutions (includes the Gibco cell culture products)
- Analytical Instruments
- Specialty Diagnostics
- Laboratory Products and Biopharma Services
- Geographic Presence:
- Global presence with operations in North America (dominant market), Europe, Asia Pacific (fastest growing), and the rest of the world.
- Key Offerings:
- Cell Freezing Media: Gibco brand products, including:
- Recovery Cell Culture Freezing Medium (optimized DMSO-based)
- Synth-a-Freeze Cryopreservation Medium (chemically defined, serum-free, xeno-free options)
- CTS (Cell Therapy Systems) products for clinical and GMP-grade cryopreservation.
- Related Products: Cryogenic storage equipment (e.g., TSX Universal Series ULT freezers), cell culture media, reagents, and instruments.
- End-Use Industries Served:
- Pharmaceutical and Biotechnology Companies (largest segment)
- Academic and Research Institutes
- Biobanks and Clinical Laboratories
- IVF Clinics
- Key Developments and Strategic Initiatives:
- Mergers & Acquisitions: Continual pursuit of strategic acquisitions to enhance its offering in high-growth areas like cell and gene therapy manufacturing support.
- Partnerships & Collaborations: Ongoing collaborations with leading biopharma companies and research institutions to develop optimized solutions for complex cell therapies.
- Product Launches/Innovations:
- April 2024: Introduced new ENERGY STAR Certified TSX Universal Series ULT freezers with enhanced temperature management and faster recovery periods, supporting better cell sample storage.
- May 2025: Launched a new line of GMP-grade cryopreservation and single-use consumables for cell therapy manufacturing (as noted in GMP market reports).
- Capacity Expansions/Investments: Significant investments in expanding global manufacturing and service capabilities, particularly in the bioprocessing and cell therapy sectors.
- Regulatory Approvals: Focus on providing products with regulatory support, such as their CTS (Cell Therapy Systems) product line, which is designed for clinical use and supported by extensive documentation.
- Distribution channel strategy: Direct sales force, global e-commerce platform (ThermoFisher.com), and authorized distributors, leveraging its massive global footprint.
- Technological Capabilities/R&D Focus:
- Core Technologies/Patents: Expertise in cell culture formulation, cryoprotectant optimization (DMSO and non-DMSO), and manufacturing of high-quality, reproducible cell culture consumables (Gibco).
- Research & Development Infrastructure: Extensive global R&D centers focused on life science solutions and advanced therapeutics.
- Innovation Focus Areas: Development of serum-free, animal-component-free, and fully chemically defined cryopreservation media for sensitive cell types (e.g., Pluripotent Stem Cells, T-cells) to support clinical and GMP-grade applications.
- Competitive Positioning:
- Strengths & Differentiators: Unmatched brand recognition (Gibco), vast product portfolio covering the entire cell culture workflow, global supply chain, and strong regulatory support for clinical-grade products.
- Market presence & ecosystem role: Dominant market leader, acting as a crucial end-to-end solutions provider for research, bioproduction, and clinical applications.
- SWOT Analysis:
- Strengths: Global scale, powerful brands (Gibco, Nalgene), deep R&D resources, vertically integrated solutions.
- Weaknesses: High reliance on acquisition-led growth, complexity of a massive product portfolio.
- Opportunities: Explosive growth in cell and gene therapy, rising demand for GMP-grade, defined media.
- Threats: Intense competition from Merck KGaA and BioLife Solutions, raw material supply chain disruptions.
- Recent News and Updates:
- Press Releases: Often feature new instrument releases and general corporate financial results. The focus in 2024-2025 is on solutions supporting the rapidly growing cell and gene therapy segment.
- Industry Recognitions/Awards: Routinely receives recognition for its laboratory equipment and life science innovations.
Top Company 2: Merck KGaA
Company Overview
- Corporate Information:
- Headquarters: Darmstadt, Germany
- Year Founded: 1668
- Ownership Type: Public (DAX: MRK) with the Merck family holding the majority stake. U.S. and Canadian business operates as MilliporeSigma.
- History and Background:
- The world's oldest operating chemical and pharmaceutical company. The current form, Merck KGaA, maintains a separate identity from the former U.S. subsidiary, Merck & Co., which operates as a distinct entity.
- Its Life Science business, which includes cell freezing media, was significantly strengthened by the acquisition of Millipore in 2010 and Sigma-Aldrich in 2015.
- Key Milestones/Timeline:
- 2010: Acquisition of Millipore Corporation, forming EMD Millipore.
- 2015: Acquisition of Sigma-Aldrich, creating MilliporeSigma in the U.S. and Canada, dramatically expanding the Life Science portfolio, including reagents and cell culture.
- Ongoing: Continual focus on expanding bioprocessing and cell and gene therapy product lines.
- Business Overview:
- A leading science and technology company operating in three sectors: Life Science, Healthcare, and Electronics. The Life Science business (MilliporeSigma) is a major global supplier of tools, technologies, and services for research, development, and bioproduction.
- Business Segments/Divisions:
- Life Science (further split into Process Solutions, Research Solutions, and Applied Solutions)
- Healthcare (Pharmaceuticals)
- Electronics
- Geographic Presence:
- Highly global, with a strong footprint across all major regions: Europe, North America, and Asia Pacific.
- Key Offerings:
- Cell Freezing Media: Portfolio under the MilliporeSigma brand, including:
- Ready-to-use cell freezing media (e.g., Cell Freeze Freeze Media, CryoMaxx).
- DMSO-based and serum-free/chemically defined formulations.
- Cryopreservation solutions for specific cell lines (stem cells, primary cells).
- Related Products: Extensive range of cell culture media, reagents (Sigma-Aldrich), filtration, purification, and bioprocessing equipment.
- End-Use Industries Served:
- Pharmaceutical and Biotechnology Companies
- Academic and Government Research Institutes
- Industrial and Applied Testing Laboratories
- Biobanks
- Key Developments and Strategic Initiatives:
- Mergers & Acquisitions: Continues to strategically acquire companies to bolster its bioprocessing and advanced therapeutics capabilities.
- Partnerships & Collaborations: Focuses on joint development agreements with CDMOs and biopharma clients to provide integrated bioprocessing solutions.
- Product Launches/Innovations:
- April 2024: Launched the first all-in-one genetic stability assay to accelerate biosafety testing for cell and gene therapies, a supporting element for cryopreservation workflow.
- Emphasis on new chemically defined and animal-component-free cryopreservation media to ensure safety and lot-to-lot consistency.
- Capacity Expansions/Investments: Investing significantly in its global manufacturing network to meet the increasing demand for bioprocessing and cell therapy materials.
- Regulatory Approvals: Strong emphasis on providing the documentation (e.g., Drug Master Files) and quality assurance (ISO, GMP compliance) required for clinical and commercial manufacturing.
- Distribution channel strategy: Global e-commerce platform (SigmaAldrich.com), direct sales for key Life Science accounts, and a network of specialized third-party distributors.
- Technological Capabilities/R&D Focus:
- Core Technologies/Patents: Expertise in media formulation science (MilliporeSigma), biopurification technologies, and analytical tools.
- Research & Development Infrastructure: Large global R&D footprint, with a strong focus on innovation for next-generation bioprocessing and personalized medicine.
- Innovation Focus Areas: Developing high-viability, closed-system-compatible cryopreservation solutions, and media components optimized for specific cell and gene therapy workflows.
- Competitive Positioning:
- Strengths & Differentiators: Broad and high-quality portfolio from research grade (Sigma-Aldrich) to clinical/production grade (Millipore), strong global reputation, and a leading position in bioprocessing technologies.
- Market presence & ecosystem role: A highly competitive global market player offering a comprehensive range of chemicals and consumables, challenging Thermo Fisher Scientific in research and bioproduction.
- SWOT Analysis:
- Strengths: Brand power (Sigma-Aldrich, Millipore), broad chemical and life science product range, strong European presence, focus on bioprocessing.
- Weaknesses: Integration challenges following multiple large acquisitions (e.g., Sigma-Aldrich), complex organizational structure (Merck KGaA vs. Merck & Co.).
- Opportunities: Expansion of cell and gene therapy manufacturing support, growth in personalized medicine applications.
- Threats: Aggressive competition in bioprocessing, potential for new, more stable cryopreservation methods to disrupt the market.
- Recent News and Updates:
- Press Releases: Often highlight financial performance, and in the Life Science sector, new bioprocessing solutions and R&D tools.
- Industry Recognitions/Awards: Regularly recognized for its work in sustainability and innovation in the life science and healthcare sectors.
R&D
Extensive research and development are needed to determine the optimal cooling rates and cryoprotectant concentrations (such as DMSO and glycerol) for cell freezing media in order to guarantee high cell viability after thawing.
Key Companies Include: Thermo Fisher Scientific, Merck KGaA, BioLife Solutions, Lonza, Corning Incorporated, Fujifilm Irvine Scientific, and Miltenyi Biotec
Clinical Trials and Regulatory Approvals
For cell freezing media used in therapeutic applications, regulatory approvals and clinical trials are essential. Before being approved for human use on the market, extensive testing is required to demonstrate safety and efficacy.
Key Companies Include: Merck KGaA, Thermo Fisher Scientific, BioLife Solutions, Lonza, Fujifilm Irvine Scientific, ReNeuron Group, and Patheon
Packaging and Serialization
Cell freezing media packaging and serialization procedures need to guarantee traceability and sterility. Proper packaging is essential for preserving the product's integrity during storage and transportation.
Key Companies Include: Peli BioThermal, Sonoco Thermasafe, CSafe, Va-Q-tec, Thermo Fisher Scientific, BioLife Solutions, and Antares Vision Group
- In October 2024, NB-KUL DF, a chemically defined cryomedia free of DMSO that is poised to revolutionize cryopreservation standards, was introduced by Nucleus Biologics, a prominent supplier of cell culture and bioprocessing solutions for the cell and gene therapy (CGT) sector.
- In September 2024, a new aseptic micro-connector that attaches directly to the freeze cassettes used in cell and gene therapy (CGT) processing was introduced today by CPC (Colder Products Company), a division of Dover and a top producer of connection technologies used in biopharmaceutical processing.
Collaborate with our experts to explore the Cell Freezing Media Market at sales@towardshealthcare.com
